Rasburicase for Hyperuricemia

Inclusion Criteria: * \<18 years of age * Patient with newly diagnosed hematological malignancies presenting with hyperuricemia: * Uric acid \> 7.5 mg/dL in patients ≥ 13 years old- Uric acid \> 6.5mg/dL in patients \<13 years old Or, patient with newly diagnosed hematological malignancies presenting with high tumor burden defined: * Non-Hodgkin's lymphoma, Stage IV regardless of uric acid level, * Non-Hodgkin's Lymphomas stage III regardless of uric acid level with one of the following: * At least one lymph node or mass \>5 cm in diameter * LDH ≥ 3 x ULN (IU/L): Judging according to modified Murphy's classification * Acute leukemia with white blood cell count (WBC) ≥ 50,000/mm3 or LDH ≥ 3 x ULN (IU/L) regardless of uric acid level. etc. Exclusion Criteria: * Patients who have received or are scheduled to receive other investigational drugs in 30 days prior to the start of SR29142 administration or during the trial period. * Low birth weight infant (\<2500g) or gestational age \<37 weeks * Patients who have received or are scheduled allopurinol within 72 hrs prior to the first dose of SR29142 or during the trial period. * Known history of severe allergic reaction and/or severe asthma. * Known history or family history of glucose-6-phosphate dehydrogenase deficiency. * Known history of hemolysis and methemoglobinemia. * Severe disorders of liver or kidney. ALT (GPT) \> 5.0 x ULN, Total Bilirubin \> 3.0 x ULN, Creatinine \> 3.0 x ULN * Uncontrollable infections (including viral infections). * Known positive tests for HBs antigen, HCV antibodies, or HIV-1, 2 antibodies. etc.